Investigational drug · Phase 2
TQB2916
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Soft Tissue Sarcoma, Melanoma, Pancreatic Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: May 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TQB2916"
First trial start
2024
Jul 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB2916", any sponsor or status.
Conditions studied
As listed on its trial records.
- Soft Tissue Sarcoma
- Melanoma
- Pancreatic Cancer
Approved drugs for the same conditions: Melanoma · Pancreatic cancer · Sarcoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB2916" as an intervention, largest first.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT05213767 · 190 participants (planned) · Start Feb 2022 · Primary completion May 2023
Drug: TQB2916 injection · For: Advanced Tumors
Sites: Tianjin, China
- TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid TumorsNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06500091 · 54 participants (planned) · Start Jul 2024 · Primary completion Jun 2026
Drug: TQB2916 injection + doxorubicin hydrochloride for injection; TQB2916 injection+penpulimab injection · For: Soft Tissue Sarcoma; Melanoma
Sites: Beijing, China; Zhengzhou, China; Changsha, China · 11 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06962267 · 50 participants (planned) · Start Apr 18, 2025 · Primary completion Aug 2027
Drug: TQB2916 Injection; Chemotherapy · For: Pancreatic Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Soft Tissue Sarcoma
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- ChiauranibCS2164Phase 33 trials
Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
- 1.0% IP-001IP-001Phase 32 trials
Immunophotonics, Inc. · Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer
- Tigilanol TiglateEBC-46Phase 22 trials
QBiotics Group Limited · Soft Tissue Sarcoma, Head and Neck Cancer
- CYT-0851Phase 21 trial
Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.